Contrast-Induced Encephalopathy Resulting From Use of Ioversol and Iopromide. Issue 1 (January 2020)
- Record Type:
- Journal Article
- Title:
- Contrast-Induced Encephalopathy Resulting From Use of Ioversol and Iopromide. Issue 1 (January 2020)
- Main Title:
- Contrast-Induced Encephalopathy Resulting From Use of Ioversol and Iopromide
- Authors:
- Zhang, Guilian
Wang, Heying
Zhao, Lili
Li, Tao
Sun, Man
Zhang, Yiheng
Hu, Hua
Teng, Guoliang
Chen, Jingju
Jian, Yating
Liu, Jiao - Abstract:
- Abstract : Background: Contrast-induced encephalopathy (CIE) is a rare disease, whose etiology and risk factors remain unclear and need investigation. Methods: We collected 7 CIE cases from 2646 patients injected with ioversol and 5 CIE cases from 526 patients injected with iopromide, all of whom underwent neurointervention surgery in our regional centers. The incidence of CIE, its characteristics, and risks were analyzed in both groups. Results: The overall incidence of CIE was 0.38%, specifically 0.95% and 0.26% in the iopromide and ioversol groups, respectively; the former incidence was significantly higher than the latter ( P = 0.029). The risk of CIE with iopromide was 3.567 to 3.618 times higher than that with ioversol (single-factor analysis odds ratio [OR], 3.618; 95% confidence interval [CI], 1.144–11.443; P = 0.029; multifactor analysis OR, 3.567 (95% CI, 0.827–15.379); P = 0.088). Moreover, acute cerebral infarction was an independent risk factor for CIE (OR, 4.024; 95% CI, 1.137–14.236; P = 0.031). Contrast-induced encephalopathy could occur within 5 minutes after injecting contrast media. The CIE characteristics differed according to the medium. In the ioversol group, the most common characteristic was visual disorder (71.43%), whereas in the iopromide group, the most common characteristic was delirium (100%). Conclusions: Compared with ioversol, iopromide appeared more likely to lead to CIE. Acute cerebral infarction was an independent risk factor for CIE. TheAbstract : Background: Contrast-induced encephalopathy (CIE) is a rare disease, whose etiology and risk factors remain unclear and need investigation. Methods: We collected 7 CIE cases from 2646 patients injected with ioversol and 5 CIE cases from 526 patients injected with iopromide, all of whom underwent neurointervention surgery in our regional centers. The incidence of CIE, its characteristics, and risks were analyzed in both groups. Results: The overall incidence of CIE was 0.38%, specifically 0.95% and 0.26% in the iopromide and ioversol groups, respectively; the former incidence was significantly higher than the latter ( P = 0.029). The risk of CIE with iopromide was 3.567 to 3.618 times higher than that with ioversol (single-factor analysis odds ratio [OR], 3.618; 95% confidence interval [CI], 1.144–11.443; P = 0.029; multifactor analysis OR, 3.567 (95% CI, 0.827–15.379); P = 0.088). Moreover, acute cerebral infarction was an independent risk factor for CIE (OR, 4.024; 95% CI, 1.137–14.236; P = 0.031). Contrast-induced encephalopathy could occur within 5 minutes after injecting contrast media. The CIE characteristics differed according to the medium. In the ioversol group, the most common characteristic was visual disorder (71.43%), whereas in the iopromide group, the most common characteristic was delirium (100%). Conclusions: Compared with ioversol, iopromide appeared more likely to lead to CIE. Acute cerebral infarction was an independent risk factor for CIE. The earliest CIE onset was within 5 minutes after injecting contrast. The characteristics of CIE varied significantly for different contrast media. … (more)
- Is Part Of:
- Clinical neuropharmacology. Volume 43:Issue 1(2020)
- Journal:
- Clinical neuropharmacology
- Issue:
- Volume 43:Issue 1(2020)
- Issue Display:
- Volume 43, Issue 1 (2020)
- Year:
- 2020
- Volume:
- 43
- Issue:
- 1
- Issue Sort Value:
- 2020-0043-0001-0000
- Page Start:
- Page End:
- Publication Date:
- 2020-01
- Subjects:
- contrast -- ioversol -- iopromide -- risk factor -- encephalopathy
Neuropharmacology -- Periodicals
615.78 - Journal URLs:
- http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=toc&D=yrovft&AN=00002826-000000000-00000 ↗
http://journals.lww.com/clinicalneuropharm/pages/default.aspx ↗
http://journals.lww.com ↗ - DOI:
- 10.1097/WNF.0000000000000374 ↗
- Languages:
- English
- ISSNs:
- 0362-5664
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.310600
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 17066.xml